Company / Accounts Receivable
Relay Therapeutics, Inc. Accounts Receivable History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$306.0K
FY2022
5-year range
$306.0K / $403.0K
FY2020-FY2022
Trend
-24.1%
vs FY2021
Sector context
#112 of 115
Health Care
What the data says
Among 115 Health Care companies, Relay Therapeutics, Inc. is in the bottom 3% for accounts receivable. Declined from $75M to $306,000 over the past 2 years.
Based on SEC 10-K filings.
$306,000 in FY2022.
Declined from $75M to $306,000 over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 115This company $306.0K Sector average $1.1B
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2022, accounts receivable decreased 24.1% year-over-year.
- Ranks #112 out of 115 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $306.0K | -24.1% |
| FY2021 | $403.0K | -99.5% |
| FY2020 | $75.0M | - |
| FY2019 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 30, 2026